Point72 Asset Management L.P. Purchases New Holdings in Savara Inc (NASDAQ:SVRA)

Point72 Asset Management L.P. bought a new position in shares of Savara Inc (NASDAQ:SVRA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 700,987 shares of the company's stock, valued at approximately $2,152,000. Point72 Asset Management L.P. owned approximately 0.41% of Savara at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its position in Savara by 4.6% in the fourth quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company's stock worth $25,512,000 after acquiring an additional 365,959 shares in the last quarter. Deerfield Management Company L.P. Series C increased its holdings in shares of Savara by 23.2% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 7,964,000 shares of the company's stock valued at $24,449,000 after purchasing an additional 1,498,223 shares in the last quarter. Nantahala Capital Management LLC lifted its stake in shares of Savara by 45.2% in the fourth quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company's stock valued at $23,103,000 after purchasing an additional 2,344,308 shares during the period. Farallon Capital Management LLC boosted its holdings in Savara by 49.9% during the fourth quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company's stock worth $20,983,000 after buying an additional 2,275,000 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Savara by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 2,784,037 shares of the company's stock worth $8,549,000 after buying an additional 57,187 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "buy" rating and set a $6.00 price target on shares of Savara in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $8.83.

Savara Price Performance

SVRA stock traded down $0.09 on Monday, reaching $2.84. The company had a trading volume of 716,088 shares, compared to its average volume of 1,305,522. The company's fifty day moving average is $2.97 and its 200 day moving average is $2.99. The company has a market cap of $490.86 million, a P/E ratio of -6.60 and a beta of 0.44. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara Inc has a 1 year low of $2.26 and a 1 year high of $5.11.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). On average, research analysts forecast that Savara Inc will post -0.45 earnings per share for the current year.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.